Clinical Efficacy of Two Different Methods to Initiate Sensor-Augmented Insulin Pumps: A Randomized Controlled Trial
Aim. To analyze clinical effect of a novel approach to initiate sensor-augmented insulin pumps in type 1 diabetes mellitus (T1DM) patients through early real-time continuous glucose monitoring (RT-CGM) initiation. Methods. A 26-week pilot study with T1DM subjects randomized (1 : 1) to start RT-CGM t...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2016/4171789 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850208049488199680 |
|---|---|
| author | Jesus Moreno-Fernandez Francisco Javier Gómez Maria Ángeles Gálvez Moreno Justo P. Castaño |
| author_facet | Jesus Moreno-Fernandez Francisco Javier Gómez Maria Ángeles Gálvez Moreno Justo P. Castaño |
| author_sort | Jesus Moreno-Fernandez |
| collection | DOAJ |
| description | Aim. To analyze clinical effect of a novel approach to initiate sensor-augmented insulin pumps in type 1 diabetes mellitus (T1DM) patients through early real-time continuous glucose monitoring (RT-CGM) initiation. Methods. A 26-week pilot study with T1DM subjects randomized (1 : 1) to start RT-CGM three weeks before continuous subcutaneous insulin infusion (CGM pre-CSII) or adding RT-CGM three weeks after continuous subcutaneous insulin infusion (CGM post-CSII). Results. Twenty-two patients were enrolled with a mean age of 36.6 yr. (range 19–59 yr.) and T1DM duration of 16.8±10.6 yr. Higher adherence in CGM pre-CSII patients was confirmed at study end (84.6±11.1% versus 64.0±25.4%; P=0.01). The two intervention groups had similar HbA1c reduction at study end of −0.6% (P=0.9). Hypoglycemic event frequency reduction was observed from baseline to study end only in CGM pre-CSII group (mean difference in change, −6.3%; 95% confidence interval, −12.0 to −0.5; P=0.04). Moreover, no severe hypoglycemia was detected among CGM pre-CSII subjects during the study follow-up (0.0±0.0 events versus 0.63±1.0 events; P=0.03). CGM pre-CSII patients showed better satisfaction than CGM post-CSII patients at the end of the study (27.3±9.3 versus 32.9±7.2; P=0.04). Conclusions. CGM pre-CSII is a novel approach to improve glycemic control and satisfaction in type 1 diabetes sensor-augmented pump treated patients. |
| format | Article |
| id | doaj-art-999dcc680b1c4baa86f8ccfeb9305d6a |
| institution | OA Journals |
| issn | 2314-6745 2314-6753 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-999dcc680b1c4baa86f8ccfeb9305d6a2025-08-20T02:10:19ZengWileyJournal of Diabetes Research2314-67452314-67532016-01-01201610.1155/2016/41717894171789Clinical Efficacy of Two Different Methods to Initiate Sensor-Augmented Insulin Pumps: A Randomized Controlled TrialJesus Moreno-Fernandez0Francisco Javier Gómez1Maria Ángeles Gálvez Moreno2Justo P. Castaño3Service of Endocrinology and Nutrition, Ciudad Real General University Hospital, SESCAM, Ciudad Real, SpainService of Endocrinology and Nutrition, La Mancha-Centro General Hospital, SESCAM, Alcázar de San Juan, Ciudad Real, SpainService of Endocrinology and Nutrition, Reina Sofia University Hospital, Maimónedes Institute of Biomedical Research of Córdoba (IMIBIC), Córdoba, SpainMaimónedes Institute of Biomedical Research of Córdoba (IMIBIC), University of Córdoba, CIBERObn, Córdoba, SpainAim. To analyze clinical effect of a novel approach to initiate sensor-augmented insulin pumps in type 1 diabetes mellitus (T1DM) patients through early real-time continuous glucose monitoring (RT-CGM) initiation. Methods. A 26-week pilot study with T1DM subjects randomized (1 : 1) to start RT-CGM three weeks before continuous subcutaneous insulin infusion (CGM pre-CSII) or adding RT-CGM three weeks after continuous subcutaneous insulin infusion (CGM post-CSII). Results. Twenty-two patients were enrolled with a mean age of 36.6 yr. (range 19–59 yr.) and T1DM duration of 16.8±10.6 yr. Higher adherence in CGM pre-CSII patients was confirmed at study end (84.6±11.1% versus 64.0±25.4%; P=0.01). The two intervention groups had similar HbA1c reduction at study end of −0.6% (P=0.9). Hypoglycemic event frequency reduction was observed from baseline to study end only in CGM pre-CSII group (mean difference in change, −6.3%; 95% confidence interval, −12.0 to −0.5; P=0.04). Moreover, no severe hypoglycemia was detected among CGM pre-CSII subjects during the study follow-up (0.0±0.0 events versus 0.63±1.0 events; P=0.03). CGM pre-CSII patients showed better satisfaction than CGM post-CSII patients at the end of the study (27.3±9.3 versus 32.9±7.2; P=0.04). Conclusions. CGM pre-CSII is a novel approach to improve glycemic control and satisfaction in type 1 diabetes sensor-augmented pump treated patients.http://dx.doi.org/10.1155/2016/4171789 |
| spellingShingle | Jesus Moreno-Fernandez Francisco Javier Gómez Maria Ángeles Gálvez Moreno Justo P. Castaño Clinical Efficacy of Two Different Methods to Initiate Sensor-Augmented Insulin Pumps: A Randomized Controlled Trial Journal of Diabetes Research |
| title | Clinical Efficacy of Two Different Methods to Initiate Sensor-Augmented Insulin Pumps: A Randomized Controlled Trial |
| title_full | Clinical Efficacy of Two Different Methods to Initiate Sensor-Augmented Insulin Pumps: A Randomized Controlled Trial |
| title_fullStr | Clinical Efficacy of Two Different Methods to Initiate Sensor-Augmented Insulin Pumps: A Randomized Controlled Trial |
| title_full_unstemmed | Clinical Efficacy of Two Different Methods to Initiate Sensor-Augmented Insulin Pumps: A Randomized Controlled Trial |
| title_short | Clinical Efficacy of Two Different Methods to Initiate Sensor-Augmented Insulin Pumps: A Randomized Controlled Trial |
| title_sort | clinical efficacy of two different methods to initiate sensor augmented insulin pumps a randomized controlled trial |
| url | http://dx.doi.org/10.1155/2016/4171789 |
| work_keys_str_mv | AT jesusmorenofernandez clinicalefficacyoftwodifferentmethodstoinitiatesensoraugmentedinsulinpumpsarandomizedcontrolledtrial AT franciscojaviergomez clinicalefficacyoftwodifferentmethodstoinitiatesensoraugmentedinsulinpumpsarandomizedcontrolledtrial AT mariaangelesgalvezmoreno clinicalefficacyoftwodifferentmethodstoinitiatesensoraugmentedinsulinpumpsarandomizedcontrolledtrial AT justopcastano clinicalefficacyoftwodifferentmethodstoinitiatesensoraugmentedinsulinpumpsarandomizedcontrolledtrial |